Business Context and Reporting Period
Company: Novartis AG
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Full Year ended December 31, 2003, and Fourth Quarter 2003
Date of Filing: January 23, 2004
Overview: Novartis reported record full-year sales and net income, driven by double-digit growth in both Pharmaceuticals and Consumer Health divisions. The company advanced to the global #5 rank among pharmaceutical companies based on market share gains in the US, Japan, and Europe.
Key Financial Metrics
| Metric (USD millions) | Full Year 2003 | Full Year 2002 | % Change (USD) |
|---|---|---|---|
| Group Sales | 24,864 | 20,877 | 19% |
| Pharmaceuticals Sales | 16,020 | 13,528 | 18% |
| Consumer Health Sales | 8,844 | 7,140 | 24% |
| Operating Income | 5,889 | 5,092 | 16% |
| Operating Margin | 23.7% | 24.4% | -0.7 pts |
| Net Income | 5,016 | 4,725 | 6% |
| Free Cash Flow | 3,628 | 2,958 | 23% |
| Basic EPS (USD) | 2.03 | 1.88 | 8% |
| Proposed Dividend (CHF) | 1.00 | 0.95 | 5% |
Balance Sheet and Liquidity
- Total Equity: USD 30.4 billion (up from USD 28.3 billion in 2002).
- Net Liquidity: USD 7.3 billion (Cash and equivalents of USD 13.3 billion less financial debt).
- Debt/Equity Ratio: 0.20:1 (unchanged from prior year).
- Credit Rating: AAA (Standard & Poor's and Moody's).
Material Changes vs. Prior Period
- Sales Growth Drivers: 8 percentage points of growth attributed to volume, 2 points to acquisitions, 1 point to price increases, and 8 points to currency translation effects.
- Pharmaceuticals: Cardiovascular (+36%) and Oncology (+36%) franchises were primary drivers. Key brands Diovan, Gleevec/Glivec, and Zometa showed significant growth.
- Consumer Health: Sandoz (generics) grew 60% in sales, driven by US retail business and the integration of Lek. OTC, CIBA Vision, and Medical Nutrition also delivered double-digit growth.
- Operating Income: Rose 16% despite a 32% increase in R&D investments (to 15.1% of sales). Cost of goods sold and Marketing & Sales expenses grew slower than sales.
- Net Income: Growth (6%) was lower than operating income growth due to reduced non-operating income from associated companies (specifically a loss booked from Roche Holding AG) and lower financial income.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- 2004 Expectations: Management expects strong top-line growth in the high single-digit range in local currencies. Both full-year operating and net income are expected to exceed 2003 levels.
- R&D Pipeline: The pipeline includes 79 projects in clinical development/registration, with 10 new medicines in late-stage development. The Cambridge research center build-up is scheduled for completion in 2004.
- Investment Strategy: R&D investments are projected to continue increasing overproportionately in 2004.
Risks and Contingencies
- Forward-Looking Statements: Results depend on regulatory approvals, clinical trial results, patent protection, and government pricing pressures.
- Associated Companies: Volatility in results from associated companies (e.g., Roche Holding AG) impacted net income.
- Accounting Adjustments: Significant differences exist between IFRS and US GAAP reporting, particularly regarding purchase accounting, pension provisions, and share-based compensation.
Investor Verification Checklist
- Currency Impact: Verify the extent of USD translation effects (8 percentage points of sales growth) versus organic local currency growth (11%).
- US GAAP Reconciliation: Review the reconciliation of Net Income and Equity from IFRS to US GAAP, noting significant adjustments for purchase accounting and share-based compensation.
- R&D Spend: Confirm the sustainability of the 32% increase in R&D investment and its impact on future margins.
- Associated Company Exposure: Assess the volatility risk from the stake in Roche Holding AG, which contributed a significant loss in 2003.
- Dividend Payout: Verify the proposed dividend increase to CHF 1.00 and its impact on free cash flow.